Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 15;17(3):281.
doi: 10.3390/ijms17030281.

Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach

Affiliations
Review

Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach

Natalia Nuño-Lámbarri et al. Int J Mol Sci. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that can progress to nonalcoholic steatohepatitis, cirrhosis and cancer. It is considered an emerging health problem due to malnourishment or a high-fat diet (HFD) intake, which is observed worldwide. It is well known that the hepatocytes' apoptosis phenomenon is one of the most important features of NAFLD. Thus, this review focuses on revealing, through a proteomics approach, the complex network of protein interactions that promote fibrosis, liver cell stress, and apoptosis. According to different types of in vitro and murine models, it has been found that oxidative/nitrative protein stress leads to mitochondrial dysfunction, which plays a major role in stimulating NAFLD damage. Human studies have revealed the importance of novel biomarkers, such as retinol-binding protein 4, lumican, transgelin 2 and hemoglobin, which have a significant role in the disease. The post-genome era has brought proteomics technology, which allows the determination of molecular pathogenesis in NAFLD. This has led to the search for biomarkers which improve early diagnosis and optimal treatment and which may effectively prevent fatal consequences such as cirrhosis or cancer.

Keywords: NAFLD; mitochondrial dysfunction; proteomics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mitochondrial proteins altered by high-fat diet.
Figure 2
Figure 2
Activation and inhibition of different proteins in NAFLD.

References

    1. Ballestri S., Zona S., Targher G., Romagnoli D., Baldelli E., Nascimbeni F., Roverato A., Guaraldi G., Lonardo A. Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2015 doi: 10.1111/jgh.13264. - DOI - PubMed
    1. Petta S., Valenti L., Bugianesi E., Targher G., Bellentani S., Bonino F., Special Interest Group on Personalised Hepatology of the Italian Association for the Study of the Liver (AISF) A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Dig. Liver Dis. 2016;48:333–342. - PubMed
    1. Lomonaco R., Sunny N.E., Bril F., Cusi K. Nonalcoholic fatty liver disease: Current issues and novel treatment approaches. Drugs. 2013;73:1–14. doi: 10.1007/s40265-012-0004-0. - DOI - PubMed
    1. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2015 doi: 10.1002/hep.28431. - DOI - PubMed
    1. Fuchs M. Non-alcoholic Fatty liver disease: The bile Acid-activated farnesoid x receptor as an emerging treatment target. J. Lipids. 2012;2012:934396. doi: 10.1155/2012/934396. - DOI - PMC - PubMed

Publication types

LinkOut - more resources